Abstract
Kawasaki disease (KD) has become the leading cause of acquired heart disease in developed countries. Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose). Therapy administered within the first 10 days of the onset of the illness has been shown to reduce arterial wall inflammation and thereby prevent the development of coronary artery aneurysm formation.
The majority of patients with KD will respond to conventional therapy. However, the management of nonresponders and patients with complications (such as acute thrombosis and chronic coronary artery changes) remains controversial. In this review article, we address some of these controversies and also describe newer treatment modalities that have been used in the management of patients with KD, both in the acute and convalescent stages of the disease.
Similar content being viewed by others
References
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Jpn J Allergy 1967; 16: 178–222
Rose V. Kawasaki syndrome: cardiovascular manifestations. J Rheumatol 1990; 17Suppl. 24: 11–4
Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gamma globulin for Kawasaki disease. Lancet 1984; II: 1055–8
Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341–7
Newburger JW, Takahashi M, Beiser AS, et al. A single infusion of intravenous gamma globulin compared to four daily doses in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633–9
Yanagawa H, Yashiro M, Nakamura Y, et al. IV gamma globulin treatment of Kawasaki disease in Japan: results of a nationwide survey. Acta Paediatr 1995; 84: 765–8
Rowley AH, Duffy CE, Shulman ST. Prevention of giant coronary artery aneurysms in Kawasaki disease by intravenous gamma globulin therapy. J Pediatr 1988; 113: 290–4
Newburger JW, Sanders SP, Burns JC, et al. Left ventricular contractility and function in Kawasaki syndrome: effect of intravenous gamma-globulin. Circulation 1989; 79: 1237–46
Rosenfeld EA, Shulman ST, Corydon KE, et al. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 1995; 126: 1000–3
Fasano MB. Risks and benefits of intravenous immunoglobulin treatment in children. Curr Opin Pediatr 1995; 7: 688–94
Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991; 33(6): 805–10
Nakano H, Ueda K, Saito A, et al. Scoring method for identifying patients with Kawasaki disease at high risk of coronary artery aneurysms. Am J Cardiol 1986; 58: 739–42
Kusakawa S. Long-term administrative care of Kawasaki disease. Acta Paediatr Jpn Overseas Ed 1983; 25: 205–9
Koren G, Silverman E, Sundel R. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr 1991; 118: 456–9
Takahashi M, Mason W, Kawasaki syndrome, Reye syndrome, and aspirin [letter]. Pediatrics 1986; 77(4): 616–7
Lee JH, Hung HY, Huang FY Kawasaki disease with Reye syndrome: report of one case. Chung-Hua Min Kuo Hsiao Erh Ko I Hseuh Hui Tsa Chih 1992; 33(1): 67–71
Koren G, Schaffer F, Silverman E, et al. Determinants of low serum concentrations of salicylates in patients with Kawasaki disease. J Pediatr 1988; 112: 663–7
Kusakawa S, Tatara K. Efficacies and risks of aspirin in the treatment of Kawasaki disease. Prog Clin Biol Res 1987; 250: 401–13
Terai M, Shulman ST. The prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131: 888–93
Burns JC, Capparelli E, Brown JA, et al. Intravenous gamma globulin treatment and retreatment in Kawasaki Disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998; 17: 1144–8
Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993; 123: 657–9
Shulman ST, Rowley AH. Treatment of Kawasaki disease with corticosteroids [letter]. J Pediatr 1996; 129: 484–5
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175–9
Kan Z, Hoshino K, Ogawa K, et al. Steroid-aspirin combination therapy for treatment of Kawasaki disease [in Japanese]. J Pediatr Pract 1990; 53: 328–31
Wright DA, Newburger JW, Baker A et al. Treatment of immune globulin resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128: 146–9
Takahashi K, Naoe S, Oharaseki T, et al. Autopsy cases of Kawasaki disease with ruptured coronary aneurysms. 6th International Kawasaki Disease Symposium; 1999 Feb 11–14; Waikoloa, Hawaii
Sugimura T, Kato H, Inoue O, et al. Intravascular ultrasound of coronary arteries in children: assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994; 89: 258–65
Suzuki A, Yamagishi M, Kimura K, et al. Functional behavior and morphology of the coronary artery wall in patients with Kawasaki disease assessed by intravascular ultrasound. J Am Coll Cardiol 1996; 27: 291–6
Fam WM, McGregor M. Effect of nitroglycerin and dipyridamole on regional coronary resistance. Circ Res 1968; 22: 649–59
Feldman RL, Nichols WW, Pepine CJ, et al. Acute effect of intravenous dipyridamole on regional coronary hemodynamics and metabolism. Circulation 1981; 64: 333–4
Kobayashi T, Sone K. Effect of dipyridamole on the blood flow in coronary aneurysms resulting from Kawasaki disease. Pediatr Cardiol 1994; 15: 263–7
Terai M, Ogata M, Sugimoto K, et al. Coronary arterial thrombi in Kawasaki disease. J Pediatr 1985; 106: 76–8
Katayama F, Hiraishi S, Takeda N, et al. Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction. Heart 1997; 78(6): 621–2
Kato H, Inoue O, Ichinose E, et al. Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction. Acta Paediatr Jpn 1991; 33: 27–35
Liang CD, Huang SC, Su WJ, et al. Successful intravenous streptokinase treatment of a child with Kawasaki disease complicated by acute myocardial infarction. Catheterization Cardiovasc Diagn 1995; 35(2): 139–45
Tsubata S, Ichida F, Hamamichi A, et al. Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease. Pediatr Cardiol 1995; 16: 186–9
Horigome H, Sekijima T, Miyamoto T. Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease. Heart 1997; 78(5): 517–8
Checchia PA, Pahl E, Shaddy RE, et al. Cardiac transplantation for Kawasaki disease. Pediatrics 1997; 100(4): 695–9
Furukawa S, Matsubara T, Umezawa Y, et al. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr 1994; 153: 663–7
Westphalen MA, McGrath MA, Kelly W, et al. Kawasaki disease with severe peripheral ischemia: treatment with prostaglandin E1 infusion. J Pediatr 1988; 112: 431–3
Tomita S, Chung K, Mas M, et al. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis 1992; 14(1): 121–6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shingadia, D., Shulman, S.T. New Perspectives in the Drug Treatment of Kawasaki Disease. Pediatr-Drugs 1, 291–297 (1999). https://doi.org/10.2165/00128072-199901040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128072-199901040-00005